


FC131 TFA

Cat. No.:	HY-P1104A
Molecular Formula:	C ₃₈ H ₄₈ F ₃ N ₁₁ O ₈
Molecular Weight:	843.85
Sequence Shortening:	Cyclo[[d-Tyr]-RR-{NaI}-G]
Target:	CXCR; HIV
Pathway:	GPCR/G Protein; Immunology/Inflammation; Anti-infection
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (296.26 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	1.1850 mL	5.9252 mL	11.8504 mL
	5 mM	0.2370 mL	1.1850 mL	2.3701 mL
	10 mM	0.1185 mL	0.5925 mL	1.1850 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (2.46 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (2.46 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (2.46 mM); Clear solution 			

BIOLOGICAL ACTIVITY

Description	FC131 TFA is a CXCR4 antagonist, inhibits [¹²⁵ I]-SDF-1 binding to CXCR4, with an IC ₅₀ of 4.5 nM. Anti-HIV activity ^[1] .	
IC₅₀ & Target	¹²⁵ I-SDF-1-CXCR4 4.5 nM (IC ₅₀)	HIV

REFERENCES

[1]. Tamamura H, et al. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J Med Chem. 2005 Jan 27;48(2):380-91.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA